Old Web
English
Sign In
Acemap
>
authorDetail
>
Gwilym Thompson
Gwilym Thompson
Bristol-Myers Squibb
Hepatocellular carcinoma
Oncology
Sorafenib
Internal medicine
Medicine
2
Papers
26
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
2020
Journal of Clinical Oncology
Julien Edeline
Thomas Yau
Joong Won Park
Masatoshi Kudo
Kwang Hyub Han
Philippe Mathurin
Philippe Merle
Richard S. Finn
Tobias Müller
Fiona Taylor
Mike Greenwood
Damir Begic
Marina Tschaika
Christine Yip
Emma Pranschke
Kim Cocks
Gwilym Thompson
Steven I Blum
T Wisniewski
Bruno Sangro
Show All
Source
Cite
Save
Citations (26)
Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
2019
Journal of Clinical Oncology
Sharlene Gill
Dena H. Jaffe
Marc DeCongelio
Arnold N. Dubell
Jing Shi
Tami Wisniewski
Gwilym Thompson
Show All
Source
Cite
Save
Citations (0)
1